AstraZeneca PLC (AZN) reports a robust 21% revenue increase for 2024, while navigating market challenges and strategic ...

Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts.

Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, ...

A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.

Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Growing at a rate of knots from the Cambridge Biomedical Campus, AstraZeneca hoisted its market cap to £183.58 billion and ...

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

Amazon reported $17.3 billion in advertising sales for Q4 2024, an increase of 18% -- which fell short of Wall Street ...

Amazon faced ~900 Mn FX headwind in 4Q’24 which was ~700 mn higher than assumed. For the third consecutive quarter, AWS grew ...

The Amazon company's revenue was just over the expectations, but its earnings-per-share were a substantial win.